Explore › Finding
Finding improvement
OnabotulinumtoxinA showed greater improvement than sacral neuromodulation in OAB symptom bother (-46.7 vs -38.6, mean difference 8.1, p=.002), treatment satisfaction (67.7 vs 59.8, mean difference 7.8, p=.01), and treatment endorsement (78.1 vs 67.6, mean difference 10.4, p<.001), but no differences in convenience, adverse effects subscale, or treatment preference.
Effect sizemean difference, 8.1 on OAB-q SF symptom bother
CI95% CI, 3.0 to 13.3
Follow-up6 months
ComparatorSacral neuromodulation (InterStim)
Effect summaryimprovement; mean difference, 8.1 on OAB-q SF symptom bother; CI: 95% CI, 3.0 to 13.3

Connected entities

Interventions
OnabotulinumtoxinA 200 unit powder for solution for injection vial
Conditions
Overactive Bladder
Outcomes
Overactive Bladder

Source

PMC5399419
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women A Randomized Clinical Trial
Read on PMC → · View in graph →